{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"Multizentrisches nationales IPT-Register mit begleitender Bioproben-Sammlung","eudractNumber":null,"id":8560,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-10-10T08:26:30+02:00","shortTitle":"Deutsches Immunthrombo­zytopenie-Register (D.ITP-Register)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Multizentrisches nationales ITP-Register und begleitende Bioproben Sammlung","eudractNumber":null,"id":9648,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-02-02T11:46:17+01:00","shortTitle":"Deutsches Immunthrombo­zytopenie-Register (D.ITP-Register)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Nicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikul&#228;ren Lymphomen&#160;inkl. Biomaterial-Sammlung f&#252;r Patienten mit Marginalzonenlymphom","eudractNumber":null,"id":4372,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2018-04-06T10:55:50+02:00","shortTitle":"Deutsches Register für Marginalzonenlymphome und Follikuläre Lymphome - MZoL- FL Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikul&#228;ren Lymphomen&#160;inkl. Biomaterial-Sammlung f&#252;r Patienten mit Marginalzonenlymphom","eudractNumber":null,"id":7900,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2021-02-04T15:27:44+01:00","shortTitle":"Deutsches Register für Marginalzonenlymphome und Follikuläre Lymphome - MZoL-FL Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">Deutsches Register f&#252;r Stammzelltransplantationen / EBMT\nRegistry on stem cell transplantation (DRST)</p>","eudractNumber":null,"id":6852,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2005-01-03T13:23:27+01:00","shortTitle":"Deutsches Register für Stammzelltransplantationen - MZoL-FL Register / EBMT Registry on stem cell transplantation","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC (DuCoRa-SCLC)","eudractNumber":"2022-001822-31","id":10150,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-01-07T08:54:18+01:00","shortTitle":"DuCoRa-SCLC","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospective NIS to generate real-world-data on Effectiveness and Safety of first-line therapy with Chemotherapy combined with Durvalumab followed by maintenance therapy with Durvakumab or Durvalumab + Olaparib in endometrial Cancer","eudractNumber":null,"id":11842,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06890273","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-24T10:23:30+01:00","shortTitle":"Duolife","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<u>E</u>ffekt einer <u>c</u>oordinierten <u>H</u>ilfestellung f&#252;r <u>T</u>umorpatienten durch intensivierte Supportivangebote: <u>e</u>ine <u>r</u>andomisierte kontrollierte Studie","eudractNumber":null,"id":2820,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2016-12-16T15:02:20+01:00","shortTitle":"ECHTER-001","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Inflammation w&#228;hrend ECMO Therapie und Weaning von der ECMO. Eine vergleichende randomisierte Studie.","eudractNumber":null,"id":10981,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05640635","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-07-21T13:35:56+02:00","shortTitle":"ECMOWean","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Ergebnisqualit&#228;t bei Darmkrebs: Identifikation von Unterschieden und Ma&#223;nahmen zur fl&#228;chendeckenden Qualit&#228;tsentwicklung","eudractNumber":null,"id":10690,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-01-01T08:53:12+01:00","shortTitle":"EDIUM","therapeutical":false,"therapyLines":[]}]}